Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALATINE: PALbociclib in Advanced Breast Cancer
NCT03870919Active, not recruiting
- Sponsor
- Unicancer
- Start
- Oct 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of palbociclib in breast cancer, sponsored by Unicancer. Primary endpoint: Overall survival rate at 24 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03870919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870919.